Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Arcellx, Inc. (ACLX : NSDQ)

• Company Description    Arcellx Inc. is a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases. Arcellx Inc. is based in GAITHERSBURG, Md. Number of Employees: 163

• Price / Volume Information    Yesterday's Closing Price: $65.20 Daily Weekly Monthly 20 Day Moving Average: 1,076,030 shares Shares Outstanding: 57.82 (millions) Market Capitalization: $3,770.05 (millions) Beta: 0.36 52 Week High: $94.07 52 Week Low: $47.86 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -4.75% -4.59% 12 Week -26.24% -27.43% Year To Date 0.00% 0.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 800 BRIDGE PARKWAY - REDWOOD CITY,CA 94065 USA ph: 240-327-0630 fax: - ir@arcellx.com http://www.arcellx.com

• General Corporate Information    Officers Rami Elghandour - Chief Executive Officer and Chairman Michelle Gilson - Chief Financial Officer Olivia Ware - Director Kavita Patel - Director Derek Yoon - Director Peer Information Arcellx, Inc. (CORR.) Arcellx, Inc. (RSPI) Arcellx, Inc. (CGXP) Arcellx, Inc. (BGEN) Arcellx, Inc. (GTBP) Arcellx, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 03940C100 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 02/26/26 Share - Related Items Shares Outstanding: 57.82 Most Recent Split Date: (:1) Beta: 0.36 Market Capitalization: $3,770.05 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.12 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.95 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 10.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 02/26/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 8.20 Price/Cash Flow: - Price / Sales: 105.02 EPS Growth vs. Year Ago Period: -106.25% vs. Previous Quarter: -5.32% Sales Growth vs. Year Ago Period: -80.99% vs. Previous Quarter: -34.49% ROE 12/31/25 - - 09/30/25 - -51.13 06/30/25 - -43.04 ROA 12/31/25 - - 09/30/25 - -33.09 06/30/25 - -27.41 Current Ratio 12/31/25 - - 09/30/25 - 3.99 06/30/25 - 3.81 Quick Ratio 12/31/25 - - 09/30/25 - 3.99 06/30/25 - 3.81 Operating Margin 12/31/25 - - 09/30/25 - -607.01 06/30/25 - -329.93 Net Margin 12/31/25 - - 09/30/25 - -607.01 06/30/25 - -329.93 Pre-Tax Margin 12/31/25 - - 09/30/25 - -602.73 06/30/25 - -326.84 Book Value 12/31/25 - - 09/30/25 - 7.95 06/30/25 - 7.12 Inventory Turnover 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Equity 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00 Debt-to-Capital 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00

Powered by Zacks Investment Research ©